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Human kallikrein-related peptidase 2 (KLK2) is a key serine
protease in semen liquefaction and prostate cancer together
with KLK3/prostate-specific antigen. In order to decipher the
function of its potential N-glycosylation site, we produced pro-
KLK2 in Leishmania tarentolae cells and compared it with its
non-glycosylated counterpart from Escherichia coli expression.
Mass spectrometry revealed that Asn-95 carries a core glycan,
consisting of two GlcNAc and three hexoses. Autocatalytic acti-
vation was retarded in glyco-pro-KLK2, whereas the activated
glyco-form exhibited an increased proteolytic resistance. The
specificity patterns obtained by the PICS (proteomic identifica-
tion of protease cleavage sites) method are similar for both
KLK2 variants, with a major preference for P1-Arg. However,
glycosylation changes the enzymatic activity of KLK2 in a dras-
tically substrate-dependent manner. Although glyco-KLK2 has
a considerably lower catalytic efficiency than glycan-free KLK2
toward peptidic substrates with P2-Phe, the situation was
reverted toward protein substrates, such as glyco-pro-KLK2
itself. These findings can be rationalized by the glycan-carrying
99-loop that prefers to cover the active site like a lid. By contrast,
the non-glycosylated 99-loop seems to favor a wide open con-
formation, which mostly increases the apparent affinity for the
substrates (i.e. by a reduction of Km). Also, the cleavage pattern
and kinetics in autolytic inactivation of both KLK2 variants can
be explained by a shift of the target sites due to the presence of
the glycan.These striking effects of glycosylationpave theway to
a deeper understanding of kallikrein-related peptidase biology
and pathology.
After early studies in the 1930s, when Frey, Kraut, andWerle
characterized the first human kallikrein and derived a name
from the Greek word for pancreas,  (reviewed in
Refs. 1 and 2), the gene for this kallikrein (KLK1) was not dis-
covered until 1985 (3, 4). During the late 1980s, two further
genes with high structural similarity toKLK1, designatedKLK2
(glandular kallikrein) (5) and the most noted member KLK3
(prostate-specific antigen) (6), were cloned and found to colo-
calize with KLK1 to the same chromosomal region (19q13.4)
(7). These three proteases share the unique extended “kallikrein
loop” (8) that corresponds to the 99-loop of other (chymo)tryp-
tic proteases. In KLK1–3, this loop partly covers the catalytic
cleft (9) and seems to affect enzymatic specificity and turnover
(8, 10). Moreover, variation within this loop is believed to con-
tribute to functional diversity in kallikrein-related peptidases
(KLKs)3 and their distinct physiological roles (11).
KLK2 displays 80% amino acid sequence identity with KLK3
(12). In vivo, KLK2 is synthesized as prepropeptide and modi-
fied through the secretory pathway. It is predominantly
expressed in prostatic tissue (13, 14), and upon cleavage of the
signal peptide, it is secreted as an inactive proenzyme, which is
able to autoactivate to gain enzymatic activity (9, 15). KLK24 is
a tryptic serine protease (16) and is able to activate single chain
urokinase-type plasminogen activator and pro-KLK3 (17). The
later finding suggests a possible physiological role for KLK2 in
the regulation of KLK3 activity. In addition, both KLK3 and
KLK2 can digest the major gel-forming proteins in semen (e.g.
semenogelin I (SEMG1) and II (SEMG2)) as well as fibronectin
(16), resulting in the liquefaction of the seminal clot prior to
impregnation. However, the majority of KLK2 protein in sem-
inal plasma has been found in complex with protein C inhibitor
(18). Its activity is also regulated by several protease inhibitors,
such as2-antiplasmin,1-antichymotrypsin, antithrombin III,
2-macroglobulin, and plasminogen activator inhibitor-1 (19–
22). Recently, KLK2 has been implicated in carcinogenesis and
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tumor metastasis of prostate cancer (23), whereas it is a useful
serum marker of prostate cancer due to its association with
prostatic proliferative disorders and tissue specificity (24, 25).
All KLKs are secreted proteases, and most of them will be
glycosylated in the Golgi (26). KLK glycosylation might be
required for proper folding, protection against proteolysis
(autolysis), and regulation of enzymatic activity (26). KLK1 and
-2 harbor one (KLK2) and two sequons (KLK1), respectively
(i.e. typical amino acid triplets of the Asn-Xaa-Ser/Thr type for
glycosylation) in their extended kallikrein/99-loop.
In KLK2, this single potential N-linked glycosylation site at
Asn-95 is most probably glycosylated in the natural protease
due to the apparent molecular mass of 31 kDa on SDS-PAGE
(27). Protein glycosylation is an important post-translational
modification in cell-cell recognition, ligand binding, antigen
presentation, pathogen binding, and protein folding and stabil-
ity (28–30). For example, changes in glycosylation patterns
have been observed for KLK3 in prostate cancer (31) and for
KLK6 ovarian cancer (32). However, the function of glycans in
these proteases has not yet been fully understood. In the pres-
ent study, we obtained glycosylated KLK2 from a eukaryotic
expression system (LEXSY) and evaluated the role of N-glyco-
sylation in KLK2 by comparison with the non-glycosylated
form from E. coli or deglycosylated LEXSY-KLK2.
Experimental Procedures
Plasmid Construction, Leishmania Expression, and Purifica-
tion of Human KLK2—Restriction enzymes and T4 ligase were
obtained from Fermentas, (St. Leon-Rot, Germany), and Pfu
Ultra II Fusion HS DNA polymerase was from Stratagene (La
Jolla, CA). E. coli strains XL1 Blue and XL2 Blue (Stratagene)
were used for subcloning expression constructs. All other
chemicals, of the highest purity available, were either from
Merck (Darmstadt, Germany), AppliChem (Darmstadt, Ger-
many), or Sigma-Aldrich. The genes encoding mature KLK2
(Ile-16–Pro-245a) and the dead mutant KLK2S195A were
cloned into the pQE-30 vector (Qiagen) with a His6 tag preced-
ing the optimized enterokinase recognition sequence SGDR
(9). Based on these templates, the encoding DNA fragments
were amplified by PCR using a forward primer (CTAGTCTA-
GAGCATCACCATCACCATCACGGATCC)withanXbaI re-
striction site and a reverse primer (CTAGGCGGCCGCCTA-
GGGGTTGGCTGCGATGGTGTC) with a NotI restriction
site (Eurofins MWG Operon, Martinsried, Germany). Subse-
quently, the PCR product was cloned in the pLEXSY-sat2 vec-
tor (Jena Bioscience) utilizing the XbaI and NotI restriction
sites. The expression constructs carried an N-terminal signal
sequence for secretory expression in the LEXSY medium.
The Leishmania tarentolae laboratory strain P10 (LEXSY,
Jena Bioscience, Germany) was maintained at 26 °C as static
suspension culture in 25-cm2 plastic cell culture flasks contain-
ing 10ml of BHI medium (Jena Bioscience) containing 5 
g/ml
hemin, 50 units/ml penicillin, and 50 
g/ml streptomycin, and
was diluted 20-fold into fresh medium every 3–4 days. The
expression constructs were linearized by SwaI digestion and
electroporated into the LEXSY cells. Clones were selected fol-
lowing the manufacturer’s instructions. Inoculation was done
from a middle-late logarithmic phase growing preculture
(A600 1.0). The expression of the secreted protein was evalu-
ated by immunoblots of conditionedmediumwith an anti-His5
antibody. For large scale production of prostatic KLKs, cells
were cultivated in 2-liter flasks filled with 500 ml of nutrient
medium and shaken at 140 rpm at 26 °C in the dark for 48 h.
The final A600 was about 3.0.
Media containing the secreted pro-KLK2 were harvested by
centrifugation at 4,500 rpm for 30 min. The supernatant was
incubatedwith nickel-nitrilotriacetic acid affinity resin (Qiagen
Inc., Valencia, CA) at 4 °C for 4 h or overnight. Zymogen forms
of KLK2 were eluted from the nickel-nitrilotriacetic acid resin
with 50 mM imidazole and subsequently processed by C-termi-
nally His-tagged enterokinase in a molar ratio of 1000:1 over-
night at room temperature. To remove enterokinase and the
KLK2 zymogen, the digested mixture was applied to benzami-
dine affinity chromatography and immobilized metal affinity
chromatography (GE Healthcare, Uppsala, Sweden). Mature
KLK2 bound to the benzamidine column and flowed through
the metal affinity material. As a final step, size exclusion chro-
matography was performed with a Superose 6 10/300 GL col-
umn connected to an ÄKTA FPLC system (GE Healthcare)
under 5 mMTris-HCl, pH 8.0, 50 mMNaCl. Fractions that con-
tained KLK2 were collected and concentrated.
Deglycosylation and Mass Spectrometry Determination—To
removeN-linked oligosaccharides, 16 
g of purified pro-KLK2
from LEXSY cells were deglycosylated with 500 units of
PNGase F (NewEngland Biolabs, Frankfurt/Main, Germany) in
50 mM sodium phosphate, pH 7.5, at room temperature. The
reaction was terminated with sample buffer, and proteins were
detected on a 15% SDS-polyacrylamide gel.
For mass spectrometry, 50 
g of pro-KLK2 were incubated
with 150 units of PNGase F for 24 h, leading to partial deglyco-
sylation, and stored in a freezer before the test. The solutionwas
digested by trypsin and the proteolytic fragments were
sequenced by means of mass spectrometry with a Q-Exactive
LC-MS/MS system (Thermo Scientific). Data analysis was per-
formed with PEAKS 7 (Bioinformatics Solutions).
Enzymatic Assays and Proteomic Identification of Protease
Cleavage Sites (PICS) Analysis—Bz-PFR-pNA, H-PFR-AMC,
ChromozymX, and PPACKwere obtained from Bachem (Weil
am Rhein, Germany), whereas Ac-OFR-AMC was a product of
California Peptide (Napa, California). KLK2 activity was deter-
mined in 50 mM Tris (pH 7.5), 100 mMNaCl, 10% (v/v) DMSO,
0.1% (w/v) bovine serum albumin (BSA) at 37 °C containing
70–500 nM KLK2, depending on the active fraction of the sam-
ple (see below). The maximum substrate concentration ranged
from 0.7 to 10 mM, depending on the respective turnover and
signal, respectively. The signal of the released pNA was mea-
sured photometrically at 405 nm, whereas that of released
AMC was fluorimetrically recorded at excitation and emission
wavelengths of 380 and 460 nm on an InfiniteM200microplate
reader in triplicate or higher multiplicate samples (Tecan,
Männedorf,Switzerland).RelativeabsorbanceforthepNAstan-
dard (Sigma-Aldrich) and relative fluorescence for the AMC
standard (Sigma) were measured at the same conditions and
used in the calculations of the rate of product formation. The
initial velocity of substrate turnover was fitted to theMichaelis-
Menten equation by error-weighted non-linear regression
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analysis to obtain kcat and Km. Substrate depletion was limited
to10%. The fraction of active KLK2was determined by active
site titration with the irreversible inhibitor PPACK by measur-
ing the activity againstH-PFR-AMC. kcat valueswere calculated
by dividing Vmax through the active protease concentrations,
which were 15.5% for KLK2e and 45.3% for glyco-KLK2. Data
fitting was performed with the ORIGIN software (OriginLab).
PICS analysis was done with samples of KLK2e and LEXSY-
derived glyco-KLK2 (33, 34). A variant of the original PICS
method was used.5 Briefly, E. coli was grown in LB medium.
Cells were lysed, and lysates were digested by either trypsin or
GluC (34). The peptide digest was further purified by C18 solid
phase extraction (Sep-Pak, Waters) according to the manufac-
turer’s instructions. KLK2e or glyco-KLK2 was incubated with
the library at a 1:300 ratio for 3 h at 37 °C in 50mMTris (pH7.5),
100 mM NaCl. The reaction was stopped by 1 
M PMSF. Pro-
tease-treated and control samples were isotopically labeled by
triplex reductive dimethylation, as described elsewhere (35).
Liquid chromatography-tandem mass spectrometry was per-
formed on a Q-Exactive plus mass spectrometer coupled to an
Easy nanoLC 1000 (both from Thermo Scientific) with a flow
rate of 300 nl/min. Buffer A was 0.5% formic acid, and buffer B
was 0.5% formic acid in acetonitrile (water and acetonitrile
were at least HPLC gradient grade quality). A gradient of
increasing organic proportion was used for peptide separation
(5–40% acetonitrile in 80 min). The analytical column was an
Acclaim PepMap column (2-
m particle size, 100-Å pore size,
length 150 mm, inner diameter 50 
m) (Thermo Scientific).
Themass spectrometer operated in data-dependentmodewith
a top 10 method at a mass range of 300–2000. For spectrum to
sequence assignment, X! Tandem (version 2013.09.01) was
used (36). The E. coli proteome database (strain K12, reference
proteome) was used as described previously (37), consisting of
4304 protein entries and 8608 randomized sequences, derived
from the originalE. coli proteome entries. The decoy sequences
were generated with the software DB toolkit (38). X! Tandem
parameters included precursor mass error of 10 ppm (Q-Ex-
active), fragment ion mass tolerance of 20 ppm (Q-Exactive),
semi-GluC specificity with up to one missed cleavage, and the
following static residue modifications: cysteine carboxyamido-
methylation (57.02 Da) and lysine and N-terminal dimethyl-
ation (light formaldehyde, 28.03 Da; medium formaldehyde,
32.06 Da; heavy formaldehyde, 36.08 Da). X! Tandem results
were further validated by PeptideProphet (39) at a confidence
level of 95%. Peak areas for relative quantitation were calcu-
lated by XPRESS (40). Semispecific peptides that are increased
8-fold in the KLK2-treated samples were considered as KLK2
cleavage products. The corresponding prime or non-prime
sequences were determined bioinformatically through data-
base lookup. Web-PICS was used to generate a heat map style
representation of protease specificity (41).
Autoproteolysis of KLK2—Active KLK2 was concentrated to
2.5 mg/ml, and the time-dependent activity loss at room tem-
perature (23 °C) was monitored toward the most sensitive
substrateH-PFR-AMC.The observed kinetic data fit well to the
second-order reaction mechanism (R2  0.975). An equal
amount of KLK2 autolysis samples was evaluated with 16%
SDS-PAGE under reducing conditions and visualized by stain-
ing with Coomassie Brilliant Blue. The stained gels were
scanned, and the percentage of autolysis KLK2 was evaluated
based on the residual intact KLK2 protein using a pixel-based
densitometer program, Un-Scan-It software (Silk Scientific).
Cleavage of Pro-KLK2 and Fibronectin—Degradation of pro-
KLK2 S195A and fibronectin by prostatic KLK2 was visualized
by SDS-PAGE and Coomassie Blue staining. For fibronectin
degradation, 50
g of purified human serum fibronectin (Inno-
vative Research, Novi, MI) were incubated with 0.5
g of KLK2
from E. coli or LEXSY cells for different periods of time (0, 1, 2,
4, and 24 h) at 37 °C in 50mMTris-HCl, pH 8.0, containing 0.1%
Nonidet P-40, 150 mM NaCl. As a control, corresponding
amounts of fibronectin or protease aloneweremonitored at the
identical condition. Degradation of pro-KLK2 S195A was car-
ried out by incubating 25 
g of pro-KLK2 S195A with 5 
g of
active KLK2 (E. coli or LEXSY) or 48 ng of enterokinase at
37 °C, for 0, 1, 2, 4, and 24 h. The cleavage was terminated by
mixing with SDS loading buffer and boiling for 5 min immedi-
ately after a given time point.
Results
Recombinant Expression, Purification, and Characteriza-
tion—In order to produce mature KLK2 (Ile-16–Pro-245a), a
short artificial propeptide encoding a His tag followed by an
optimized cleavage site for enterokinase, His6-(Gly-Ser)-Ser-
Gly-Asp-Arg, was added to the N terminus. Pro-KLK2 was
secreted by Leishmania cells with an average protein yield of
about 0.9 mg/liter of culture, and its identity was confirmed by
mass spectrometry. After immobilized metal affinity chroma-
tography, it appeared as a single band on an SDS-polyacryl-
amide gel. The propeptide was removed with enterokinase,
generating mature KLK2, which was subjected to gel filtration
on a Superdex 75 column. The protein eluted as a single peak
with an apparent molecular mass of 27 kDa corresponding to
the monomer. Unfortunately, mature KLK2 could not be sepa-
rated from enterokinase clipping products because the frag-
ments were held together by disulfide bonds and exhibited sim-
ilar properties as mature, intact KLK2 on ion exchange,
benzamidine affinity chromatography, and size exclusion chro-
matography columns (Fig. 1A). Edman degradation confirmed
the correct N-terminal sequence Ile-Val-Gly-Gly-Trp-Glu-X-
Glu-Lys (where X corresponds to Cys in the KLK2 sequence).
Furthermore, mature KLK2 was active toward the chromo-
genic substrate Bz-PFR-pNA.
Expression of pro-KLK2 in Leishmania cells lead to a defined
band of 27 kDa on SDS-polyacrylamide gels, which shifted
upon PNGase F treatment to 26 kDa, corresponding to a loss of
a short N-glycan from the KLK2 (Fig. 1B). The glycosylation
was further confirmed by glycan staining (periodic acid-Schiff
staining) and mass spectrometry, the latter indicating attach-
ment of two GlcNAc units and three hexoses at Asn-95, (Fig.
1C), which are most likely the mannose units of a eukaryotic
core glycan linked to the only potential N-glycosylation site of
KLK2 (Fig. 1D). The glycan cannot be cleaved by EndoH, which
5 M. L. Biniossek, M. Niemer, K. Maksimchuk, B. Mayer, J. Fuchs, P. F. Huesgen,
D. G. McCafferty, B. Turk, G. Fritz, G. Haecker, L. Mach, and O. Schilling,
manuscript in preparation.
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removes onlyN-linked sugars containingmore than threeman-
nose moieties (42). This short glycan increases the molecular
mass from 26.18 to 27.08 kDa, in agreement with the observed
bands on SDS gels.
Activation of Pro-KLK2—The same artificial propeptide as
described above, comprising a His6 tag and an optimized rec-
ognition sequence for enterokinase activation, was employed in
the production of pro-KLK2 in E. coli (referred to as pro-KLK2e
hereafter). After in vitro folding, KLK2e turned out to be fully
maturated, indicating a spontaneous autoactivation. By con-
trast, during LEXSY cell expression, the soluble pro-KLK2 was
secreted into the medium and had initially no enzymatic activ-
ity toward the Bz-PFR-pNA substrate and underwent only slow
autoactivation. This activation was corroborated by an accu-
mulation of the KLK2 band on SDS-PAGE (Fig. 2A, lanes 2–4)
and a corresponding slow increase of fluorogenic activity (Fig.
2B, black line). The 20 kDa band, which occurs after 48 h, is part
of a KLKmolecule that was clipped at the Arg-70–His-71 bond
but is held together by two disulfides under oxidizing condi-
tions (12). However, the autoactivation is strongly time- and
concentration-dependent: increasing the pro-KLK2 concen-
tration in the range of 250–900 
g/ml did not enhance but
rather decreased generation of mature KLK2 after 24 h (Fig.
2C). This apparent paradox can be explained by the second-
order reaction of the in trans autocleavage of KLK2, which
results in accelerated inactivation with higher protein concen-
tration (Fig. 2C).We further investigatedwhether glycosylation
influences the activation and autoactivation process of pro-
KLK2 (Fig. 2D). Autoactivation of glycosylated KLK2 and enzy-
matically deglycosylated KLK2 was qualitatively similar and
slow as judged by SDS-PAGE (Fig. 2A), which correlates well
with the fluorogenic activity of glyco- and deglyco-KLK2 sam-
ples (Fig. 2B).
To reduce the complexity of the autoactivation reaction, we
produced the dead mutant pro-KLK2-S195A in LEXSY cells to
abolish the positive feedback of the activated product. We
added 20% KLK2 either from E. coli or LEXSY to “activate” the
pro-KLK2-S195A dead mutant (i.e. to cleave the propeptide
and liberate the N-terminal Ile-16). Intriguingly, glycosylated
KLK2 turned out to be a considerably better activator than the
non-glycosylated enzyme (Fig. 2E), albeit still 200 times
slower than enterokinase (Fig. 2D). Nearly all pro-KLK2-S195A
molecules had been turned over by glyco-KLK2 to the mature
species within 2 h, whereas only about 10% of pro-KLK2 had
been converted in 4 h by KLK2e in a non-productive manner.
KLK2e preferentially produces an inactive 20-kDa fragment
(43) that is further degraded (Fig. 2E, lanes 4–6). By con-
trast, the mature KLK2 form (26 kDa) was further processed
by glyco-KLK2 to different fragments of 17 and 11 kDa
(Fig. 2, C and E).
Autolysis of KLK2—As already described, autoactivation is
followedby autoproteolysis (Fig. 2E). In non-glycosylatedKLK2
from E. coli, autolysis was paralleled by loss of enzymatic activ-
ity (9). To identify the potential effect of glycosylation onKLK2,
time-dependent loss ofKLK2 enzymatic activitywasmonitored
over 144 h. Like E. coliKLK2 (KLK2e), active KLK2 did undergo
autolysis with a loss of activity (Fig. 3A). Fitting of the inactiva-
tion data to the second-order rate law, d[KLK2]/dt 
k[KLK2]2 and [KLK2]t 0  100%, resulted in the rate con-
stant k 0.017 0.001 day1. Interestingly, the inactivation
FIGURE 1. Analysis of KLK2 glycosylation. A, enterokinase-activated KLK2 from Leishmania expression (LEXSY) was analyzed under non-reducing and
reducing conditions. Clippedproductsmigrated as a single bandunder non-reducing conditions. Intact and clipped forms,which form fragments smaller than
17 kDa under reducing conditions (DTT), were not separable and appeared as a single peak in gel filtration. B, removal of N-glycans from LEXSY-KLK2 with
PNGase F (36 kDa) resulted in a shift of the apparent molecular mass by about 1 kDa. C, trypsin-digest mass spectrometry confirmed partially deglycosylated
LEXSY-KLK2 by PNGase F under non-denaturing conditions. The deconvoluted mass spectrum is shown, and the indicated masses refer to uncharged
molecules. Thepeak at 2957was identifiedby sequencing and subsequentmodification search as VPVSHSFPHPLYN-(Hex3HexNAc2)-MSLLK. The signal at 2066
represents the corresponding deglycosylated peptide (VPVSHSFPHPLYD-(deglycosylated)-MSLLK), with the expected core glycanmass of 891 Da.D,N-linked
core glycans at Asn-95 of LEXSY KLK2, consisting most likely of two N-acetylglucosamine and three mannose units. PNGase F cleaves the N-glycan and
generates an Asp-95.
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rate constant is lower than the similarly determined inacti-
vation rate constant of KLK2e (0.028 day1) (9). Apparently,
glycosylation slows down the autolysis, in agreement with a
stabilizing effect of glycosylation with respect to proteolysis
(44).
The major autolysis band appeared with a molecular mass of
about 17 kDa (Fig. 3B). Sequencing of the 17 kDa band identi-
fied the five N-terminal residues of the full-length mature
enzyme (starting with Ile-16), suggesting a cleavage in the 148-
loop. Previously, a cleavage site between residues Arg-153 and
Ser-154 has been reported for natural KLK2 from seminal
plasma and insect KLK2 (18, 45). This cleavage generates two
fragments: one with a molecular mass of 17.2 kDa, which con-
sists of residues Ile-16 to Arg-153 carrying the short glycan or
oligosaccharide, and one of 9.9 kDa, corresponding to the frag-
ment Ser-154 to Pro-254a. Two additional bandswere observed
with KLK2e (Fig. 2E, lanes 3–6), which might be attributed to
the established cleavage between Arg-95e and His-95f, result-
ing in a 10.2 kDa band, including an oligosaccharide attached to
the Ile-16 to Arg-95e fragment, whereas the 16.9 kDa band
FIGURE 2.Autoactivation and activation of pro-KLK2. A, time-dependent autoactivation of both glycosylated (lanes 1–4) and enzymatically deglycosylated
pro-KLK2 (lanes 5–8) ismonitoredonanSDS-PAGE.Note the sameshift of about 1 kDaas in Fig. 1B.B, activity assayof autoactivatedKLK2with the small peptide
substrate H-PFR-AMC by glycosylated (black line) and enzymatically deglycosylated KLK2 (dotted line) at varying times (0, 24, 48, and 72 h), matching those in
A. C, concentration-dependent autoactivation of pro-KLK2-S195A. The initial pro-KLK2 samples at concentrations of 250 (lane 1), 600 (lane 2), 800 (lane 3), and
900 (lane 4)
g/ml were kept at room temperature for 1 day and subsequently at 4 °C for 4 days, respectively.D, activation of pro-KLK2. Shown is incubation of
1 
g of pro-KLK2-S195A from LEXSY cells (lane 1) with 1% KLK2e from E. coli (lane 2), 1% glyco-KLK2 from LEXSY cells (lane 3), or 0.05% (lane 4) or 0.1%
enterokinase (lane 5) overnight (14 h) at room temperature. E, pro-KLK2-S195A (lane 1) was digested by 20% KLK2e (lanes 3–6) or 20% glyco-KLK2 (lanes 7–10)
for a time-dependent course. Sampleswere taken at 0, 2, 4, and 24h, as indicatedabove the lanes, and then checkedbyCoomassie Blue-stained SDS-PAGE. The
vertical gray line was inserted to indicate samples with different treatment. KLK2e shows a different cleavage pattern (e.g. by generating a 20-kDa fragment,
which originates from the clipping at Arg-702His-71).
FIGURE 3. Time-dependent autoinactivation of KLK2. A, the decrease of intact glyco-KLK2 (black squares and line) correlates well with the loss of protease
activity (open circleswithdotted line). The loss ofmatureprotein andactivity follows a second-order reactionmechanism.B, time-dependent KLK2autolysiswas
monitored by reducing SDS-PAGE.
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corresponds to His-95f to Pro-254a, as confirmed by N-termi-
nal sequencing for KLK2e (9, 12).
Influence of Glycosylation on KLK2 Protease Specificity and
Enzyme Kinetics—Human KLK2 exhibits a predominantly
trypsin-like activity with a strong preference for Arg residues in
the P1 position, according to the Schechter and Berger nomen-
clature for peptidic substrate residues P and protease specificity
subsites S (9, 46, 47).Mass spectrometry-based profiling of pro-
tease specificity with proteome-derived peptide libraries is a
powerful method to simultaneously identify prime and non-
prime specificity determinants (i.e. on the N-terminal and the
C-terminal side of the scissile bond, respectively) (48). Here, we
used a recently developed variant of the original PICS
approach, which enables profiling of lysine specificity.5 The
peptide library was prepared from E. coli using GluC digestion,
thus enabling identification of specificity for basic residues.
Specificity profiling of KLK2e and glyco-KLK2 with this library
fromP6 to P6	 showed an overall high similarity, with P1-Arg as
major specificity determinant, with 88–89% cleavage sites (Fig.
4A). For bothKLK2e and glyco-KLK2,8% of the cleavage sites
feature a P1-Lys, thus defining P1 specificity as Arg Lys for
both KLK2 variants. In P2, a preference for aromatic residues is
observed because Phe, Trp, and Tyr together account for about
17% of both KLK2e and glyco-KLK2 cleavage sites. If this num-
ber is corrected for the natural abundance of aromatic amino
acids, their percentage rises to about 30%. In addition, Asp
seems to be a moderately preferred residue in P2 (8%). P3 is
overall unspecific and, in particular, disfavors Pro, which is not
present in any cleavage product. Also, P4 is not very specific,
although the hydrophobic, aliphatic residues Ala, Val, Ile, Leu,
andMet are found in 45% of cleavages, which decreases to 34%
by the natural abundance correction. Otherwise, the covered
prime-side specificity pockets appear to be similarly unspecific.
In P1	, the small, polar residues Ser, Thr, and Asn account for
27% (KLK2e) and 28% (glyco-KLK2) of cleavage sites, respec-
tively, whereasAla andVal contribute an additional 28% in both
cases. A tendency toward small, more hydrophobic residues is
observed in the P2	 position, with Ala, Val, Ile, and Thr seen in
51% of all cleavage products. Although some residues, such as
Asp, His, and Val or Glue, Ile, and Pro, respectively, occurmore
often in the P3	 and P4	 positions, no distinct specificity can be
assigned there.
The peptidic substrate turnover was determined using the
small fluorogenic and chromogenic substrates Ac-Orn-Phe-
Arg-AMC (where Orn represents ornithine), H-Pro-Phe-Arg-
AMC, Bz-Pro-Phe-Arg-pNA, and Mco-D-Nle-Gly-Arg-pNA
(where Nle represents norleucine; also known as Chromozym
X), respectively (Fig. 4B). The recently published data of KLK2e
for H-PFR-AMC and Bz-PFR-pNA were also included in Fig.
4C and Table 1 for comparison (9). For all P1-Phe substrates,
FIGURE4.Effects ofglycosylationonKLK2activity.A, PICSof KLK2e (left) andglyco-KLK2 (right) coveringpeptide substrates from residueP6 toP6	. Increased
occurrence of an amino acid residue in cleavage sites of a random peptide library indicates the corresponding preference of the peptidase specificity sites
S6–S6	. Both patterns are similar; P1-Arg dominates the specificity, whereas aromatic P2 residues and hydrophobic P4 residues are slightly favored. In P1	 and
P2	, small or polar residues and small to medium hydrophobic residues are preferred, respectively. B, Michaelis-Menten plot of H-PFR-AMC turnover by KLK2e
(open red circles) and glyco-KLK2 (filled orange circles). The velocity was normalized for 150 nM enzyme concentration, according to active site titrations. It is
noteworthy that the Km of glyco-KLK2 is 5 times higher than that of KLK2e, despite a comparable Vmax and kcat of 17.0 and 13.6 s
1, respectively. C, catalytic
efficiency depicted as columns for KLK2e (red) and glyco-KLK2 (orange) for fluorogenic and chromogenic substrates (Table 1). Chromozym X is Mco-D-Nle-Gly-
Arg-pNA. Whereas the kcat varies considerably, the Km for all substrates is consistently about 5 times higher with glyco-KLK2 than with KLK2e.
Glycosylated Kallikrein-related Peptidase 2
598 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 291•NUMBER 2•JANUARY 8, 2016
 at U
niversität Salzburg on January 22, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
the Km of glyco-KLK2 was consistently 5 times higher than
that of KLK2e, whereas it was even 12 times higher for Chro-
mozym X, representing a general lower affinity for small pep-
tidic substrates, lacking amino acids in the prime-side region.
Furthermore, the kcat of glyco-KLK2 was about 2-fold lower
compared with the kcat of KLK2e for Ac-OFR-AMC and Bz-
PFR-pNA, whereas it was nearly equal for H-PFR-AMC but
about 10 times higher for the turnover of ChromozymX (Table
1). The overall catalytic efficiency (kcat/Km) of KLK2e for the
best substrate, Ac-OFR-AMC, was 4,368,890 M1 s1 (i.e.more
than 13,000 times higher than for the worst, Chromzym X,
the only one with Gly instead of Phe in the P2 position). For the
three P2-Phe substrates, the catalytic efficiency of glyco-KLK2
ranged from 7 to 15% of that of KLK2e, whereas it was nearly
double the value of KLK2e for Chromozym X.
KLK2 Glycosylation Alters the Cleavage Pattern of Protein
Substrates—As observed in the activation studies using the
deadmutant glyco-pro-KLK2 S195A (Fig. 2), E. coli- and Leish-
mania-derived KLK2 exhibited a marked difference in the
cleavage pattern of this mutant. Apparently, glycosylation of
the enzyme strongly affects the preference of substrate recog-
nition sites. Non-glycosylated KLK2e hardly converted pro-
KLK2 S195A into mature KLK2, in contrast to the processing
by glyco-KLK2 (Fig. 2C). Also, further degradation products
differed distinctly. These observations suggest that the enzyme
glycosylation serves as a checkpoint for KLK2 autoactivation;
only properly glycosylated KLK2 can feed back in the activation
of glycosylated pro-KLK2.However, it is interesting to note that
non-glycosylated KLK2e is able to produce quantitative
amounts of mature KLK2e as well, requiring more time (9).
The different processing patterns of glyco-KLK2 and KLK2e
on pro-KLK2-S195A reflect differences in substrate turnover
and specificity that are not based on simple recognition of
amino acids sequences. To investigatewhether suchdifferences
in protein substrate recognition occur more generally, we
investigated the digestion of the natural, physiologically rele-
vant substrate fibronectin, which is present in seminal plasma
(22). The incubation of fibronectin with either E. coli- or
LEXSY-derived KLK2 produced a large number of peptides
(Fig. 5). In the first 4 h, the digestion patterns of fibronectin by
both KLK2 forms look nearly identical, and they still look sim-
ilar after 16 h. Subsequently, glyco-KLK2 digested the fibronec-
tin fragments somewhat more rapidly, resulting in additional
bands after 24 h, which can be found in the KLK2e sample after
a more extended incubation up to 3 days. Thus, the enzymatic
activity of glyco-KLK2 is substantially altered when it comes to
the turnover of larger protein substrates with distinct tertiary
structure and recognition sites that do not belong to small syn-
thetic substrates. Remarkably, the short single glycan linked at
Asn-95 makes KLK2 a more efficient and more specific prote-
ase for natural substrates, such as pro-KLK2 and fibronectin.
Discussion
Glycosylation is a key feature of nearly all human kallikreins,
although they vary considerably with respect to location and
glycan composition (26).We producedN-glycosylated KLK2 in
Leishmania cells (LEXSY), which generate short glycans that
correspond to the core of the more complex mammalian gly-
cans (49). In our hands, KLK2 could not be obtained frommam-
malian expression inHEK293 T/S cells. Glycoproteins secreted
from Leishmania cells are smaller (49) and very homogeneous
(Fig. 1) when compared with glycoproteins from natural
sources (18, 27, 50) or insect expression (51). Mass spectrome-
TABLE 1
Kinetic parameters of KLK2 toward synthetic substrates
For the Michaelis constants Km and the turnover number kcat, the weighted S.E. values of the non-linear regression fitting were used, whereas the error of the catalytic
efficiency was calculated according to the formula given by Fenner (76).
KLK2 sourcea Substrate Km kcat kcat/Km

M s1 M1 s1
E. coli Ac-OFR-AMCb 45 2 196.60 5.04 4,368,890 224,160
LEXSY Ac-OFR-AMC 224 11 96.05 3.97 308,260 27,520
E. coli H-PFR-AMCc 69 3 17.03 0.14 246,810 10,920
LEXSY H-PFR-AMC 378 27 13.57 0.54 35,890 2940
E. coli Bz-PFR-pNAc 75 2 5.77 0.09 76,930 2380
LEXSY Bz-PFR-pNA 448 44 2.59 0.17 5780 680
E. coli Mco-D-Nle-GR-pNAd 302 14 0.10 0.01 330 40
LEXSY Mco-D-Nle-GR-pNA 3567 317 1.95 0.10 550 60
a Expression system.
b Acetyl-Orn-Phe-Arg-AMC contains the non-proteinogenic amino acid ornithine in P3 position, which is a homolog of Lys, being shorter by one methylene group.
c The values for KLK2e with H-PFR-AMC and Bz-PFR-pNA correspond to the data of Skala et al. (9) but were corrected according to a new active site titration with PPACK,
in which KLK2e was 15.5% active, whereas the LEXSY protein showed 45.3% activity.
d Mco-D-Nle-Gly-Arg-pNA, also known as Chromozym X, has the non-natural D-norleucine in the P3 position, whereas its side chain occupies the S4 rather than the S3
subsite.
FIGURE 5.Comparative degradation rates and fragmentationpatterns of
human fibronectin in the presence of KLK2e (lanes 2–6) glyco-KLK2
(lanes 7–11) as determinedby SDS-PAGE.Aliquotswere taken at represen-
tative intervals and analyzed by SDS-PAGE followed by Coomassie Blue stain-
ing. Fibronectin alone is stable at 37 °C for at least 24 h. Overall, the break-
downbyglyco-KLK2appearsmoreefficient and results in someuniquebands
after 24-h incubation, as indicated by arrows.
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try confirmed the presence of a eukaryotic core glycan linked to
Asn-95, which typically consists of twoGlcNAc and threeman-
nose units (Fig. 1C).
Previously, we obtained pure and active KLK2e from E. coli
expression (9). A comparative proteomic specificity profiling
(PICS) of both KLK2 variants resulted in nearly identical pro-
files for the P6 to P6	 positions (Fig. 4A). The high preference
for P1-Arg over Lys with 89% versus 8% cleavages resembles the
result of a phage display studywith 98% versus 2%, in contrast to
the positional scanning measurements, where Lys reached 45%
of Arg at 100% (9, 47). Whereas the P2 position seems unspe-
cific in the phage display, it appears specific for aromatic resi-
dues, although not as pronounced as in the positional scanning.
All three approaches agree on the unspecific nature of the S3
subsite and on the acceptance of hydrophobic, aliphatic P4 res-
idues. The proteomic identification of protease cleavage sites
and phage display find small and polar residues in P1	, whereas
a tendency to hydrophobic P2	 residues is weaker in the phage
display. Bothmethods confirm the unspecific character of posi-
tion P3	 and beyond.
The enzyme kinetics of four small P1-Arg substrates showed
that glyco-KLK2 always has a significantly decreased binding
affinity, represented by an at least 5-fold higher Km, whereas
variations of the turnover rate (kcat) were not correlated (Table
1). Ac-OFR-AMC exhibits the highest catalytic efficiency,
probably because the otherwise non-proteinogenic amino acid
ornithine forms ideal backbone hydrogen bonds to both the
Gly-216 amideNHand carbonyl oxygen, in contrast to Bz-PFR-
pNA that can bind only with the Pro carbonyl oxygen to the
Gly-216 NH. According to PICS, P3-Pro is a distinctly disfa-
vored residue. However, the N-terminal P3-Pro in H-PFR-
AMC can form both hydrogen bonds to Gly-216, which may
explain its higher catalytic efficiency compared with Bz-PFR-
pNA (Table 1). Otherwise, KLK2 might prefer AMC over pNA
in the prime side, although both substrate types can have sim-
ilar kinetic parameters as for trypsin (52).
Since both specificity profiles of the proteomic identification
of protease cleavage sites show no significant differences after
cut-off of the background (Fig. 4A), the explanation for the
effect of theAsn-95 glycosylation ismost likely an altered active
site conformation near the specificity pockets S2–S4. In the
proteomic approach, KLK2e exhibited more unspecific back-
ground cleavages than glyco-KLK2, which suggests an
increased adaptability of the active site to substrates. Most
likely, the more flexible 99-loop of KLK2e favors a wide open
conformation that allows small substrates faster binding to the
active site. This process could be described by a higher kon rate,
resulting in a decreased Km, which equals (koff  kcat)/kon. In
line with this proposal, the Km for all investigated substrates
with KLK2e was always lower than 20% of the corresponding
Km of glyco-KLK2, independent of the catalytic efficiency
(Table 1). Two KLK2e structures (Protein Data Bank codes
4NFE and 4NFF) feature such an open active site and a disor-
dered, flexible 99-loop (Fig. 6A). By contrast, apo-KLK1 (Pro-
tein Data Bank code 1SPJ) is equally glycosylated at Asn-95 but
has a more rigid and half-closed 99-loop that clashes with sub-
FIGURE 6.Model of the 99-loop lid mechanism and possible regulation of KLK2 activity by glycosylation. A, the left panel shows the crystal structure of
KLK2e (Protein Data Bank code 4NFE) with the small inhibitor benzamidine as a ball-and-stick model located in the S1 pocket, which is labeled like the other
pockets from S4 to S2	, whereas themolecular surface of the wide open 99-loop is depicted in yellow. In the related KLK2e PPACK complex (Protein Data Bank
code 4NFF), P1-Arg, P2-Pro, and D-Phe occupy the non-prime region, from the S1 to the S4 subsite, respectively. It exhibits an open 99-loop, which can hardly
interfere with substrate binding. In the right panel, the structure of a human KLK3 acyl intermediate complex (Protein Data Bank code 2ZCK) represents a fully
closed, non-glycosylated 99-loop, which is homologous to the KLK2e counterpart. Parts of the 99-loop interact tightly with the P2–P4 residues, contributing
considerably to substrate specificity. B, in the left panel, the apo-KLK1 structure (Protein Data Bank code 1SPJ) contains a 99-loop with a glycosylated Asn-95,
displaying a half-open conformation, most likely due to the presence of the stabilizing glycan, of which only a GlcNAc was visible. This structure is the basis of
thePPACKglycan-99-loopmodel (middle), extendedbyoneGlcNAcand threemannoseunits of a coreglycan. PPACKandpNAorAMCsubstratebindingwould
be hampered by the rather occluding 99-loop conformation. The combinedmodel of glycosylated 99-loop with a bound substrate in the S2–S4 region (right)
suggests that the active site is less accessible in the closed state but also more stable during the following catalytic steps. A favored closed state will result in
a lower kon rate and higher Km, consistent with the observed enzyme kinetics of glyco-KLK2 and KLK2e.
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strate binding in S2–S4 (Fig. 6B). A KLK3 substrate complex
structure (Protein Data Bank code 2ZCK) suggests that the
99-loop closes like a lid on the S2–S4 subsites. In case of glyco-
KLK2 the single glycan at Asn-95 could regulate the loop
dynamics upon substrate binding by stabilizing the closed state
(Fig. 6B). Moreover, the stabilizing and rigidifying effect of the
glycan on the lidlike 99-loop,might be related to the open E and
closed E* states of the conformational selection model, influ-
encing the equilibrium of both states (9). These considerations
can explain the turnover of small substrates, whereas the more
efficient processing of protein substrates, such as pro-KLK2 or
fibronectin, by glyco-KLK2 is more complex and certainly reg-
ulated by additional parameters, such as exosite binding.
The strong enzymatic preference for P1-Arg residues of
KLK2 enables the pro-form to undergo autoactivation (9, 12,
16, 21, 45). Both glyco-KLK2, which was secreted as inactive
zymogen (Fig. 1A), and enzymatically deglycosylated KLK2
exhibit a similar autoactivation pattern (Fig. 2A). The differ-
ence from the quick autoactivator pro-KLKe could be explained
by a lower activity of glyco-KLK2 and higher stability of pro-
KLK2. Given the higher activity of glyco-KLK2 as compared
with KLK2e toward glycosylated pro-KLK2 (Fig. 2), the lower
efficiency in autoactivation of the Leishmania expressed pro-
teins dependsmost likely on the higher stability of pro-KLK2 as
substrate. Several KLKs harbor either Arg-15 or Lys-15 in the
P1 position of their propeptide, making them ideal targets for
KLK2 (Fig. 7), as observed for pro-KLK1, -2, and -3, in contrast
to pro-KLK5, -9, -11, and -12 (9, 45, 53–55).
Five internal cleavage sites of KLK2 have been reported,
including Arg-702His-71, Lys-95e2His-95f, Arg-1072Leu-
108, Arg-1532Ser-154, and Arg-2352Lys-236, which are
located on the protein surface (9, 12, 45) (Fig. 7A). Cleavages at
Lys-95e2His-95f in the 99-loop (9) and Arg-1532Ser-154 in
the 148-loop inactivate KLK2 (18, 45) (Fig. 3). Cleavage of Lys-
95e2His-95f (Fig. 7, site 3), located near the S2 pocket (9),
generates N and C termini, whichmay clash with the active site
or distort the catalytic triad at Asp-102. Twomutants of KLK2e,
K95eM andK95eQ, weremore resistant against autolysis in the
99-loop (9), while they were still slowly inactivated, probably
due to cleavages at other sites. It is noteworthy that Lys-95e is
close to Asn-95, whose glycan may shield the 99-loop and shift
the preferred cleavage to Arg-1532Ser-154 (18, 45). This inac-
tivation site in the 148-loop (Fig. 7, site 5) might disturb the
adjacent activation pocket with the N-terminal Ile-16 to Asp-
FIGURE 7. Inactivating cleavage sites of KLK2. A, stereo representation of a glyco-KLK2 model. The active site residues Asp-102, His-57, and Ser-195, and the
stabilizing salt bridge Ile-16–Asp-194 are represented as sticks. The N terminus with the beginning of the propeptide (green), the 99-loop (yellow), and the
148-loop (red) are highlighted as specified. The six cleavage sites at Arg-15, Arg-70, Lys-95e, Arg-107, Arg-153, andArg-226 are shownas red spheres. Theglycan
at Asn-95 that shields the 99-loop from cleavage is depictedwith sticks and spheres. B, sequence alignment the six KLK2 cleavage sites, as shown in A, with the
other 14 human tissue kallikrein family members and bovine chymotrypsin A (bCTRA) as a numbering reference. The red arrows indicate the autolysis sites on
KLK2,whereas its secondary structure is depicted at thebottom, and theglycosylation site at Asn-95 ismarkedwith a star. In contrast to KLK1 and -2, KLK3 is not
glycosylated in the 99-loop but at Asn-61. Identical and conserved residues are highlighted with a gray background, whereby a darker gray indicates a higher
degree of conservation. The basic P1 residues Arg and Lys in KLK2 and in the potential cleavage sites of other KLKs are highlighted with a blue background.
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194 salt bridge, which is essential for catalysis, because its dis-
ruption inactivates serine proteases (56–59). The same cleav-
age site with a Lys–Lys bond is present in KLK3 (60, 61). Given
the similarity of the cleavage site architecture of KLK2 and -3
(45), KLK2 may inactivate KLK3 in similar manner, despite a
proposed role of KLK2 as physiological activator of KLK3 (45,
62). The peptide bond between Arg-70 and His-71 of KLK2
(Fig. 7, site 2) has been shown to be targeted by FXa, which is
also present in seminal plasma (12, 63). This site is located at the
75-loop, near the cleavage site Arg-1532Ser-154 (Fig. 7, site 5),
but with less solvent exposure and accessibility, which may
explain why Arg-702His-71 cleavages were not observed for
KLK1 and -3. The autocleavage sites of KLK2 between residues
Arg-107 and Leu-108 (Fig. 7, site 4) and residues Arg-235 and
Lys-236 are located within -helices (12, 45, 64). The Arg-
1072Leu-108 cleavage site is highly conserved among human
KLK1, -3, -6, -9, -12, and -15 (Fig. 7, site 4), whereas Arg-
2352Lys-236 is only found in KLK3 (Fig. 7, site 6).
Aside from proteolytic processing, protein glycosylation can
markedly influence protein conformation, function, and regu-
lation. Apart from a dampening effect on themovements of the
flexible 99-loop, the glycanmost likely induces the formation of
a type I 	-turn, in particular when two GlcNAc are present (65,
66), in place of the Asx turn of in KLK2e. The general signifi-
cance of glycans for enzymatic activity and physiological regu-
lation can be corroborated by examples, such as the trypsin-like
human tissue-type plasminogen activator, which possesses
three N-glycosylation sites, one in the protease domain. Com-
pletely aglycosylated tissue-type plasminogen activator is up
to 4-fold more active against chromogenic substrates (67),
whereas a higher mannose content or removal of the terminal
sialicacidsenhancestheactivity(68).Otherwise,effectsofN-gly-
cosylation on structure and function may be negligible in some
cases as for partially deglycosylated human complement factor
I (69).However, therearenumerousexamples formarkedN-gly-
cosylation effects from the protease field alone, such as degly-
cosylated plasma kallikrein (KLKB1) and its glyco-form, which
exhibit considerably different cleavage patterns for protein sub-
strates (70). Also, natural, inhomogeneously glycosylated KLK3
and deglycosylated KLK3 from recombinant expression are
equally active, whereas recombinant glyco-KLK3 was 3 times
more active against small chymotryptic substrates (71). Altered
glycosylation patterns of KLK3 (31) and KLK6 (32, 72) have
been related to prostate and ovarian cancer, respectively. Mass
spectrometry identified up to 40 different glycan structures on
KLK3 (73, 74) and 11 on KLK6 (72), whereas it is hard to deter-
mine the functional role of specific natural glycosylation sites.
On the amino acid sequence level, glyco-KLK2 is identical to
non-glycosylatedKLK2e, resulting in similar biochemical prop-
erties; both pro-KLK2 forms autoactivate, both proteases pro-
cess the natural substrate fibronectin in a similar manner, and
both inactivate via internal cleavage. Besides these similarities,
glycosylation has several distinguishing effects onKLK2: (a) the
stability of pro-KLK2 increases without affecting autoactiva-
tion; (b) apparently, the active site conformation altered (Fig. 6)
and concomitantly the activity toward small substrates; (c) the
99-loop, which is the major inactivation site in KLK2e, is
shielded from cleavage, explaining the retarded autolysis; and
(d) the altered enzymatic activity generates different cleavage
patterns of pro-KLK2 as substrate. Analogously, this altered
KLK2 activity may serve as a control mechanism for KLK3 in
vivo. Remarkably, the percentage of clipped free KLK3 is highly
related to benign prostatic hyperplasia (75). Alternative protein
cleavage and glycosylation of KLK2 may correlate with the dis-
ease state, suggesting that KLK2 monitoring may increase the
sensitivity and specificity of prostate cancer markers.
Author Contributions—S. G. conducted most of the experiments,
analyzed the results, and wrote major parts of the paper. W. S. pre-
pared the KLK2e samples and measured their activity. V. M. pre-
pared PICS samples, conceived the study, and analyzed data. P. B. did
the mass spectrometry experiments and analysis. M. L. B. and O. S.
performed PICS experiments and analyzed the results. J. K. con-
ducted N-terminal sequencing and data analysis. H. B. conceived
and coordinated the study and interpreted the data. P. G. conceived
and coordinated the study, performed enzyme kinetic measure-
ments, analyzed the data, and wrote parts of the paper.
Acknowledgments—We thank Drs. Elfriede Dall and Thomas Zögg
for technical help as well as Franz Jehle and Bettina Mayer for excel-
lent technical assistance.
References
1. Raspi, G. (1996) Kallikrein and kallikrein-like proteinases: purification and
determination by chromatographic and electrophoretic methods. J. Chro-
matogr. B Biomed. Appl. 684, 265–287
2. Avgeris, M., Mavridis, K., and Scorilas, A. (2012) Kallikrein-related pepti-
dases in prostate, breast, and ovarian cancers: from pathobiology to clin-
ical relevance. Biol. Chem. 393, 301–317
3. Fukushima, D., Kitamura, N., and Nakanishi, S. (1985) Nucleotide se-
quence of cloned cDNA for human pancreatic kallikrein.Biochemistry 24,
8037–8043
4. Baker, A. R., and Shine, J. (1985) Human-kidney kallikrein: cDNA cloning
and sequence-analysis. DNA 4, 445–450
5. Schedlich, L. J., Bennetts, B. H., and Morris, B. J. (1987) Primary structure
of a human glandular kallikrein gene. DNA 6, 429–437
6. Riegman, P. H., Vlietstra, R. J., van der Korput, J. A., Romijn, J. C., and
Trapman, J. (1989) Characterization of the prostate-specific antigen gene:
a novel human kallikrein-like gene. Biochem. Biophys. Res. Commun. 159,
95–102
7. Riegman, P. H. J., Vlietstra, R. J., Klaassen, P., van der Korput, J. A. G. M.,
Geurts van Kessel, A. G., Romijn, J. C., and Trapman, J. (1989) The pros-
tate-specific antigen gene and the human glandular kallikrein-1 gene are
tandemly located on chromosome-19. FEBS Lett. 247, 123–126
8. Bode, W., Chen, Z., Bartels, K., Kutzbach, C., Schmidt-Kastner, G., and
Bartunik, H. (1983) Refined 2 Å x-ray crystal structure of porcine pancre-
atic kallikrein A, a specific trypsin-like serine proteinase. Crystallization,
structure determination, crystallographic refinement, structure and its
comparison with bovine trypsin. J. Mol. Biol. 164, 237–282
9. Skala, W., Utzschneider, D. T., Magdolen, V., Debela, M., Guo, S., Craik,
C. S., Brandstetter, H., and Goettig, P. (2014) Structure-function analyses
of human kallikrein-related peptidase 2 establish the 99-loop as master
regulator of activity. J. Biol. Chem. 289, 34267–34283
10. Carvalho, A. L., Sanz, L., Barettino, D., Romero, A., Calvete, J. J., and
Roma˜o,M. J. (2002) Crystal structure of a prostate kallikrein isolated from
stallion seminal plasma: a homologue of human PSA. J. Mol. Biol. 322,
325–337
11. Aminetzach, Y. T., Srouji, J. R., Kong, C. Y., and Hoekstra, H. E. (2009)
Convergent evolution of novel protein function in shrew and lizard
venom. Curr. Biol. 19, 1925–1931
12. Lövgren, J., Tian, S., Lundwall, A., Karp, M., and Lilja, H. (1999) Produc-
tion and activation of recombinant hK2with propeptidemutations result-
Glycosylated Kallikrein-related Peptidase 2
602 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 291•NUMBER 2•JANUARY 8, 2016
 at U
niversität Salzburg on January 22, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
ing in high expression levels. Eur. J. Biochem. 266, 1050–1055
13. Lövgren, J., Valtonen-Andre´, C., Marsal, K., Lilja, H., and Lundwall, A.
(1999) Measurement of prostate-specific antigen and human glandular
kallikrein 2 in different body fluids. J. Androl. 20, 348–355
14. Yousef, G. M., and Diamandis, E. P. (2001) The new human tissue kal-
likrein gene family: structure, function, and association to disease. Endocr.
Rev. 22, 184–204
15. Denmeade, S. R., Lo¨vgren, J., Khan, S. R., Lilja, H., and Isaacs, J. T. (2001)
Activation of latent protease function of pro-HK2, but not pro-PSA, in-
volves autoprocessing. Prostate 48, 122–126
16. Mikolajczyk, S. D., Millar, L. S., Kumar, A., and Saedi, M. S. (1998) Human
glandular kallikrein, hK2, shows arginine-restricted specificity and forms
complexes with plasma protease inhibitors. Prostate 34, 44–50
17. Takayama, T. K., Fujikawa, K., andDavie, E.W. (1997) Characterization of
the precursor of prostate-specific antigen: activation by trypsin and by
human glandular kallikrein. J. Biol. Chem. 272, 21582–21588
18. Deperthes, D., Chapdelaine, P., Tremblay, R. R., Brunet, C., Berton, J.,
He´bert, J., Lazure, C., andDube´, J. Y. (1995) Isolation of prostatic kallikrein
hK2, also known as hGK-1, in human seminal plasma. Biochim. Biophys.
Acta 1245, 311–316
19. Oesterling, J. E. (1991) Prostate specific antigen: a critical assessment of
themost useful tumor-marker for adenocarcinoma of the prostate. J. Urol.
145, 907–923
20. Robert, M., Gibbs, B. F., Jacobson, E., and Gagnon, C. (1997) Character-
ization of prostate-specific antigen proteolytic activity on its major phys-
iological substrate, the sperm motility inhibitor precursor/semenogelin I.
Biochemistry 36, 3811–3819
21. Lövgren, J., Airas, K., and Lilja, H. (1999) Enzymatic action of human
glandular kallikrein 2 (hK2): substrate specificity and regulation by Zn2
and extracellular protease inhibitors. Eur. J. Biochem. 262, 781–789
22. Deperthes, D., Frenette, G., Brillard-Bourdet, M., Bourgeois, L., Gauthier,
F., Tremblay, R. R., and Dube´, J. Y. (1996) Potential involvement of kal-
likrein hK2 in the hydrolysis of the human seminal vesicle proteins after
ejaculation. J. Androl. 17, 659–665
23. Shang, Z., Niu, Y., Cai, Q., Chen, J., Tian, J., Yeh, S., Lai, K.-P., and Chang,
C. (2014) Human kallikrein 2 (KLK2) promotes prostate cancer cell
growth via function as a modulator to promote the ARA70-enhanced
androgen receptor transactivation. Tumour Biol. 35, 1881–1890
24. Recker, F., Kwiatkowski, M. K., Piironen, T., Pettersson, K., Lu¨mmen, G.,
Wernli, M., Wiefelspu¨tz, J., Graber, S. F., Goepel, M., Huber, A., and
Tscholl, R. (1998) The importance of human glandular kallikrein and its
correlation with different prostate specific antigen serum forms in the
detection of prostate carcinoma. Cancer 83, 2540–2547
25. Meola, J., Goulart, L. R., Oliveira, J. D. D., Neves, A. F., Oliveira, W. P.,
Saraiva, A. C.M., Capaneli, A. C., Cardoso, A.M., Prado, L.D., Borba, S. A.,
and Silva, H. D. (2006) Differential expression of the KLK2 and KLK3
genes in peripheral blood and tissues of patients with prostate cancer.
Genet. Mol. Biol. 29, 193–199
26. Guo, S., Skala, W., Magdolen, V., Brandstetter, H., and Goettig, P. (2014)
Sweetened kallikrein-related peptidases (KLKs): glycan trees as potential
regulators of activation and activity. Biol. Chem. 395, 959–976
27. Frenette, G., Deperthes, D., Tremblay, R. R., Lazure, C., and Dube´, J. Y.
(1997) Purification of enzymatically active kallikrein hK2 from human
seminal plasma. Biochim. Biophys. Acta 1334, 109–115
28. Lebrilla, C. B., and An, H. J. (2009) The prospects of glycan biomarkers for
the diagnosis of diseases.Mol. Biosyst. 5, 17–20
29. Dennis, J. W., Granovsky, M., and Warren, C. E. (1999) Protein glycosyl-
ation in development and disease. Bioessays 21, 412–421
30. Varki, A., Kannagi, R., and Toole, B. P. (2009) Glycosylation changes in
cancer. in Essentials of Glycobiology (Varki, A., Cummings, R. D., Esko,
J. D., Freeze, H. H., Hart, G. W., and Marth, J. D., eds), 2nd Ed., pp.
617–632, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
31. Gilgunn, S., Conroy, P. J., Saldova, R., Rudd, P. M., and O’Kennedy, R. J.
(2013) Aberrant PSA glycosylation: a sweet predictor of prostate cancer.
Nat. Rev. Urol. 10, 99–107
32. Kuzmanov, U., Jiang, N., Smith, C. R., Soosaipillai, A., andDiamandis, E. P.
(2009) Differential N-glycosylation of kallikrein 6 derived from ovarian
cancer cells or the central nervous system. Mol. Cell. Proteomics 8,
791–798
33. Becker-Pauly, C., Barré, O., Schilling, O., auf dem Keller, U., Ohler, A.,
Broder, C., Schütte, A., Kappelhoff, R., Stöcker, W., and Overall, C. M.
(2011) Proteomic analyses reveal an acidic prime side specificity for the
astacin metalloprotease family reflected by physiological substrates.Mol.
Cell. Proteomics 10.1074/mcp.M111.009233
34. Schilling, O., Huesgen, P. F., Barre´, O., Auf dem Keller, U., and Overall,
C. M. (2011) Characterization of the prime and non-prime active site
specificities of proteases by proteome-derived peptide libraries and tan-
dem mass spectrometry. Nat. Protocols 6, 111–120
35. Boersema, P. J., Raijmakers, R., Lemeer, S., Mohammed, S., and Heck,
A. J. R. (2009)Multiplex peptide stable isotope dimethyl labeling for quan-
titative proteomics. Nat. Protoc. 4, 484–494
36. Craig, R., and Beavis, R. C. (2004) TANDEM: matching proteins with
tandem mass spectra. Bioinformatics 20, 1466–1467
37. Biniossek, M. L., and Schilling, O. (2012) Enhanced identification of pep-
tides lacking basic residues by LC-ESI-MS/MS analysis of singly charged
peptides. Proteomics 12, 1303–1309
38. Martens, L., Vandekerckhove, J., and Gevaert, K. (2005) DBToolkit: pro-
cessing protein databases for peptide-centric proteomics. Bioinformatics
21, 3584–3585
39. Keller, A., Nesvizhskii, A. I., Kolker, E., and Aebersold, R. (2002) Empirical
statistical model to estimate the accuracy of peptide identifications made
by MS/MS and database search. Anal. Chem. 74, 5383–5392
40. Han, D. K., Eng, J., Zhou, H., and Aebersold, R. (2001) Quantitative pro-
filing of differentiation-inducedmicrosomal proteins using isotope-coded
affinity tags and mass spectrometry. Nat. Biotechnol. 19, 946–951
41. Schilling, O., auf dem Keller, U., and Overall, C. M. (2011) Factor Xa
subsite mapping by proteome-derived peptide libraries improved using
WebPICS, a resource for proteomic identification of cleavage sites. Biol.
Chem. 392, 1031–1037
42. Maley, F., Trimble, R. B., Tarentino, A. L., and Plummer, T. H. (1989)
Characterization of glycoproteins and their associated oligosaccharides
through the use of endoglycosidases. Anal. Biochem. 180, 195–204
43. Grauer, L. S., Finlay, J. A., Mikolajczyk, S. D., Pusateri, K. D., andWolfert,
R. L. (1998) Detection of human glandular kallikrein, hK2, as its precursor
form and in complex with protease inhibitors in prostate carcinoma se-
rum. J. Androl. 19, 407–411
44. Rysˇlavá, H., Doubnerová, V., Kavan, D., and Vaneˇk, O. (2013) Effect of
posttranslational modifications on enzyme function and assembly. J. Pro-
teomics 92, 80–109
45. Lövgren, J., Rajakoski, K., Karp, M., Lundwall, A., and Lilja, H. (1997)
Activation of the zymogen form of prostate-specific antigen by human
glandular kallikrein 2. Biochem. Biophys. Res. Commun. 238, 549–555
46. Schechter, I., and Berger, A. (1967) On the size of the active site in pro-
teases. I. Papain. Biochem. Biophys. Res. Commun. 27, 157–162
47. Cloutier, S. M., Chagas, J. R., Mach, J. P., Gygi, C. M., Leisinger, H. J., and
Deperthes, D. (2002) Substrate specificity of human kallikrein 2 (hK2) as
determined by phage display technology. Eur. J. Biochem. 269, 2747–2754
48. Schilling, O., and Overall, C. M. (2008) Proteome-derived, database-
searchable peptide libraries for identifying protease cleavage sites. Nat.
Biotechnol. 26, 685–694
49. Breitling, R., Klingner, S., Callewaert, N., Pietrucha, R., Geyer, A., Ehrlich,
G., Hartung, R.,Müller, A., Contreras, R., Beverley, S.M., andAlexandrov,
K. (2002)Non-pathogenic trypanosomatid protozoa as a platform for pro-
tein research and production. Protein Expr. Purif. 25, 209–218
50. Herrala, A., Kurkela, R., Porvari, K., Isoma¨ki, R., Henttu, P., and Vihko, P.
(1997) Human prostate-specific glandular kallikrein is expressed as an
active and an inactive protein. Clin. Chem. 43, 279–284
51. Rajakoski, K., Piironen, T., Pettersson, K., Lo¨vgren, J., and Karp, M. (1997)
Epitope mapping of human prostate specific antigen and glandular kal-
likrein expressed in insect cells. Prostate Cancer Prostatic Dis. 1, 16–20
52. Baird, T. T., Jr., Wright, W. D., and Craik, C. S. (2006) Conversion of
trypsin to a functional threonine protease. Protein Sci. 15, 1229–1238
53. Mikolajczyk, S. D.,Millar, L. S.,Marker, K.M., Grauer, L. S., Goel, A., Cass,
M. M. J., Kumar, A., and Saedi, M. S. (1997) Ala217 is important for the
catalytic function and autoactivation of prostate-specific human kallikrein
2. Eur. J. Biochem. 246, 440–446
Glycosylated Kallikrein-related Peptidase 2
JANUARY 8, 2016•VOLUME 291•NUMBER 2 JOURNAL OF BIOLOGICAL CHEMISTRY 603
 at U
niversität Salzburg on January 22, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
54. Yoon, H., Laxmikanthan, G., Lee, J., Blaber, S. I., Rodriguez, A., Kogot,
J. M., Scarisbrick, I. A., and Blaber, M. (2007) Activation profiles and
regulatory cascades of the human kallikrein-related peptidases. J. Biol.
Chem. 282, 31852–31864
55. Yoon, H., Blaber, S. I., Debela,M., Goettig, P., Scarisbrick, I. A., and Blaber,
M. (2009) A completed KLK activome profile: investigation of activation
profiles of KLK9, 10, and 15. Biol. Chem. 390, 373–377
56. Song, H. W., Choi, S. I., and Seong, B. L. (2002) Engineered recombinant
Enteropeptidase catalytic subunit: effect of N-terminal modification.
Arch. Biochem. Biophys. 400, 1–6
57. Debela, M., Magdolen, V., Grimminger, V., Sommerhoff, C., Messer-
schmidt, A., Huber, R., Friedrich, R., Bode, W., and Goettig, P. (2006)
Crystal structures of human tissue kallikrein 4: activity modulation by a
specific zinc binding site. J. Mol. Biol. 362, 1094–1107
58. Stura, E. A., Muller, B. H., Bossus, M., Michel, S., Jolivet-Reynaud, C., and
Ducancel, F. (2011) Crystal structure of human prostate-specific antigen
in a sandwich antibody complex. J. Mol. Biol. 414, 530–544
59. Bode, W., Schwager, P., and Huber, R. (1978) The transition of bovine
trypsinogen to a trypsin-like state upon strong ligand binding: the refined
crystal structures of the bovine trypsinogen-pancreatic trypsin inhibitor
complex and of its ternary complex with Ile-Val at 1.9 Å resolution. J. Mol.
Biol. 118, 99–112
60. Christensson, A., Laurell, C. B., and Lilja, H. (1990) Enzymatic activity of
prostate-specific antigen and its reactions with extracellular serine pro-
teinase inhibitors. Eur. J. Biochem. 194, 755–763
61. Watt, K. W. K., Lee, P. J., M’Timkulu, T., Chan, W. P., and Loor, R. (1986)
Human prostate-specific antigen: structural and functional similarity with
serine proteases. Proc. Natl. Acad. Sci. U.S.A. 83, 3166–3170
62. Williams, S. A., Xu, Y., DeMarzo, A. M., Isaacs, J. T., and Denmeade, S. R.
(2010) Prostate-specific antigen (PSA) is activated by KLK2 in prostate
cancer ex vivo models and in prostate-targeted PSA/KLK2 double trans-
genic mice. Prostate 70, 788–796
63. Matsuda, Y., Shimokawa, K., Katayama, M., Shimizu, H., Umeda, T., Os-
hio, S., and Chiba, R. (2002) Blood coagulation factor X (FX) in human
seminal plasma. Arch. Androl. 48, 295–300
64. Timmer, J. C., Zhu, W., Pop, C., Regan, T., Snipas, S. J., Eroshkin, A. M.,
Riedl, S. J., and Salvesen, G. S. (2009) Structural and kinetic determinants
of protease substrates. Nat. Struct. Mol. Biol. 16, 1101–1128
65. Bosques, C. J., Tschampel, S. M., Woods, R. J., and Imperiali, B. (2004)
Effects of glycosylation on peptide conformation: a synergistic experimen-
tal and computational study. J. Am. Chem. Soc. 126, 8421–8425
66. O’Conner, S. E., and Imperiali, B. (1998) A molecular basis for glycosyla-
tion-induced conformational switching. Chem. Biol. 5, 427–437
67. Wittwer, A. J., Howard, S. C., Carr, L. S., Harakas, N. K., Feder, J., Parekh,
R. B., Rudd, P. M., Dwek, R. A., and Rademacher, T. W. (1989) Effects of
N-glycosylation on in vitro activity of Bowes melanoma and human colon
fibroblast-derived tissue plasminogen activator. Biochemistry 28,
7662–7669
68. Howard, S. C., Wittwer, A. J., andWelply, J. K. (1991) Oligosaccharides at
each glycosylation sitemake structure-dependent contributions to biolog-
ical properties of human tissue plasminogen activator. Glycobiology 1,
411–418
69. Tsiftsoglou, S. A., Arnold, J. N., Roversi, P., Crispin, M. D., Radcliffe, C.,
Lea, S. M., Dwek, R. A., Rudd, P. M., and Sim, R. B. (2006) Human com-
plement factor I glycosylation: structural and functional characterisation
of the N-linked oligosaccharides. Biochim. Biophys. Acta 1764,
1757–1766
70. Tang, J., Yu, C. L., Williams, S. R., Springman, E., Jeffery, D., Sprengeler,
P. A., Estevez, A., Sampang, J., Shrader, W., Spencer, J., Young, W.,
McGrath,M., andKatz, B. A. (2005) Expression, crystallization, and three-
dimensional structure of the catalytic domain of human plasma kallikrein.
J. Biol. Chem. 280, 41077–41089
71. Bowman, K. K., Clark, J., Yu, L., Mortara, K., Radika, K., Wang, J., and
Zhan, H. (2000) Expression, purification, and characterization of deglyco-
sylated human pro-prostate-specific antigen. Protein Expr. Purif. 20,
405–413
72. Kuzmanov, U., Smith, C. R., Batruch, I., Soosaipillai, A., Diamandis, A.,
and Diamandis, E. P. (2012) Separation of kallikrein 6 glycoprotein sub-
populations in biological fluids by anion-exchange chromatography cou-
pled to ELISA and identification by mass spectrometry. Proteomics 12,
799–809
73. Behnken, H. N., Ruthenbeck, A., Schulz, J. M., and Meyer, B. (2014) Gly-
can analysis of prostate specific antigen (PSA) directly from the intact
glycoprotein by HR-ESI/TOF-MS. J. Proteome Res. 13, 997–1001
74. White, K. Y., Rodemich, L., Nyalwidhe, J. O., Comunale, M. A., Clements,
M. A., Lance, R. S., Schellhammer, P. F., Mehta, A. S., Semmes, O. J., and
Drake, R. R. (2009) Glycomic characterization of Prostate-specific antigen
and prostatic acid phosphatase in prostate cancer and benign disease sem-
inal plasma fluids. J. Proteome Res. 8, 620–630
75. Mikolajczyk, S. D., Millar, L. S., Wang, T. J., Rittenhouse, H. G., Wolfert,
R. L., Marks, L. S., Song, W., Wheeler, T. M., and Slawin, K. M. (2000)
“BPSA,” a specific molecular form of free prostate-specific antigen, is
found predominantly in the transition zone of patients with nodular be-
nign prostatic hyperplasia. Urology 55, 41–45
76. Fenner, G. (1931) Das Genauigkeitsmass von Summen, Differenzen,
Produkten und Quotienten der Beobachtungsreihen. Naturwissen-
schaften 19, 310
Glycosylated Kallikrein-related Peptidase 2
604 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 291•NUMBER 2•JANUARY 8, 2016
 at U
niversität Salzburg on January 22, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Oliver Schilling, Josef Kellermann, Hans Brandstetter and Peter Goettig
Shihui Guo, Wolfgang Skala, Viktor Magdolen, Peter Briza, Martin L. Biniossek,
Activation and Enzymatic Activity
A Single Glycan at the 99-Loop of Human Kallikrein-related Peptidase 2 Regulates
doi: 10.1074/jbc.M115.691097 originally published online November 18, 2015
2016, 291:593-604.J. Biol. Chem. 
  
 10.1074/jbc.M115.691097Access the most updated version of this article at doi: 
 Alerts: 
  
 When a correction for this article is posted•  
 When this article is cited•  
 to choose from all of JBC's e-mail alertsClick here
  
 http://www.jbc.org/content/291/2/593.full.html#ref-list-1
This article cites 75 references, 8 of which can be accessed free at
 at U
niversität Salzburg on January 22, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
